» Articles » PMID: 30008860

Combination of Procalcitonin, C-reaction Protein and Carcinoembryonic Antigens for Discriminating Between Benign and Malignant Pleural Effusions

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Jul 17
PMID 30008860
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Pleural effusion (PE) is a common manifestation associated with certain chest diseases. However, there is no effective diagnostic marker with high sensitivity and specificity. The aim of the present study was to evaluate the diagnostic performance of several biomarkers in the use of detecting malignant pleural disorder. One hundred and fifty patients with a specific diagnosis of exudative PE were enrolled in this study and were divided into the benign PE group (n=93) and the malignant PE group (n=57). Thoracoscopy was conducted to identify the reasons for the PE. Biomarkers in pleural fluid and in sera were determined either by microparticle enzyme immunoassay [carcinoembryonic antigen (CEA)], fluorescence immunoassay [procalcitonin (PCT)] or light-scattering turbidimetric immunoassay [C-reaction protein (CRP)]. Then, correlation analysis and receiver-operating characteristic (ROC) curve analysis individually or in combination were performed. The CRP and PCT levels were higher in benign PE than they were in malignant PE (PCT: P=0.017, P=0.032; CRP: P=0.001, P<0.001, respectively), while CEA levels were lower in benign PE than in malignant PE (CEA: P=0.001, P=0.001, respectively). During the ROC curve analysis, an optimal discrimination was identified by combining pleural CRP, pleural CEA and serum (s)PCT with an area under the curve of 0.973 (sensitivity, 98.9%; specificity, 89.5%). In the diagnosis of PE, there was no single biomarker that appeared to be adequately accurate. The combination of pleural CRP, pleural CEA and sPCT may represent an efficient diagnostic procedure for guiding the patient towards follow-up clinical treatment.

Citing Articles

Cancer antigen-125 levels correlate with pleural effusions and COPD-related complications in people living at high altitude.

Li S, Ma H, Gan L, Ma X, Wu S, Li M Medicine (Baltimore). 2018; 97(46):e12993.

PMID: 30431573 PMC: 6257551. DOI: 10.1097/MD.0000000000012993.

References
1.
Shitrit D, Zingerman B, Bar-Gil Shitrit A, Shlomi D, Kramer M . Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist. 2005; 10(7):501-7. DOI: 10.1634/theoncologist.10-7-501. View

2.
Joo K, Park W, Lim M, Kwon S, Yoon J . Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases. J Korean Med Sci. 2011; 26(9):1147-51. PMC: 3172650. DOI: 10.3346/jkms.2011.26.9.1147. View

3.
Liang Q, Shi H, Qin X, Liang X, Jiang J, Yang H . Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2007; 63(1):35-41. DOI: 10.1136/thx.2007.077958. View

4.
Maskell N, Butland R . BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003; 58 Suppl 2:ii8-17. PMC: 1766019. DOI: 10.1136/thorax.58.suppl_2.ii8. View

5.
Yang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y . Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for the diagnosis of sepsis in critical patients. Ann Intensive Care. 2016; 6(1):51. PMC: 4901212. DOI: 10.1186/s13613-016-0153-5. View